Sodium –Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
In 2008, the European Medicines Agency and US Food and Drug Administration (FDA) issued industry guidance stating that all future novel glucose-lowering agent trials must undergo routine cardiovascular risk evaluation either before approval or as a post-marketing commitment.1 This mandated that all cardiovascular endpoint committees prospectively adjudicate all major adverse cardiovascular events, including cardiovascular death, non-fatal MI and stroke, occurring across Phase II and III diabetes trials.
Source: Radcliffe Cardiology - Category: Cardiology Authors: mehul Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | European Medicines Agency (EMA) | Food and Drug Administration (FDA) | Heart | Heart Failure | Marketing | Sodium | Stroke